Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Dianthus Therapeutics. The associated price target remains the same with $65.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rami Katkhuda’s rating is based on the promising clinical data presented by Dianthus Therapeutics for their C1s inhibitor, claseprubart, in treating myasthenia gravis. The Phase II MaGic study results demonstrated significant improvements in patient outcomes, such as a notable decline in MG-ADL and QMG scores, even at lower serum concentrations than initially targeted. This suggests that effective treatment can be achieved with less complement inhibition, which is a positive indicator for future studies.
Moreover, Dianthus’s plans to evaluate different dosing regimens in a pivotal study set to begin in 2026, along with additional in vitro data showing the potential for enhanced efficacy, further support the Buy rating. The company’s strategic approach to incorporate QMG-based inclusion criteria and the potential advantages of upstream inhibition with claseprubart over existing treatments highlight the therapeutic promise of their pipeline. These factors, combined with the company’s financial position, make Dianthus Therapeutics an attractive investment opportunity.
In another report released on October 17, Raymond James also maintained a Buy rating on the stock with a $63.00 price target.